Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLKNASDAQ:FGENNASDAQ:INKTNASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.28$0.22▼$1.56$29.52M0.621.15 million shs213,322 shsFGENFibroGen$0.31-2.0%$0.36$0.18▼$1.74$31.70M0.872.26 million shs921,518 shsINKTMiNK Therapeutics$7.70+2.7%$8.39$4.56▼$13.79$30.54M0.1514,628 shs1,177 shsMYNZMainz Biomed$3.53+10.3%$4.17$2.65▼$40.40$8.19M0.53103,864 shs237,378 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%+0.18%+41.94%+38.21%-67.98%FGENFibroGen0.00%+9.57%-0.03%-35.72%-69.84%INKTMiNK Therapeutics0.00%+0.92%-14.73%-12.89%-16.98%MYNZMainz Biomed0.00%+9.63%-1.40%-28.40%-89.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos4.5888 of 5 stars3.15.00.04.73.02.51.3FGENFibroGen4.5638 of 5 stars3.35.00.04.72.73.30.6INKTMiNK Therapeutics2.8239 of 5 stars3.53.00.00.03.61.70.6MYNZMainz Biomed2.9011 of 5 stars3.35.00.00.02.20.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.20Hold$2.00512.37% UpsideFGENFibroGen 2.50Moderate Buy$10.003,087.76% UpsideINKTMiNK Therapeutics 3.00Buy$37.50387.01% UpsideMYNZMainz Biomed 2.50Moderate Buy$14.00296.60% UpsideCurrent Analyst Ratings BreakdownLatest MYNZ, FGEN, ALLK, and INKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/18/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.002/25/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $35.002/20/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/14/2025MYNZMainz BiomedMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.00(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/AFGENFibroGen$29.62M1.07N/AN/A($1.87) per share-0.17INKTMiNK TherapeuticsN/AN/AN/AN/A($5.23) per shareN/AMYNZMainz Biomed$893.99K9.16N/AN/A$10.82 per share0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%5/8/2025 (Estimated)FGENFibroGen-$284.23M-$0.48N/AN/AN/A-67.66%N/A-36.17%5/5/2025 (Estimated)INKTMiNK Therapeutics-$22.46M-$2.92N/AN/AN/AN/AN/A-189.14%5/13/2025 (Estimated)MYNZMainz Biomed-$26.30M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)Latest MYNZ, FGEN, ALLK, and INKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025INKTMiNK Therapeutics-$0.61N/AN/AN/AN/AN/A5/8/2025Q1 2025ALLKAllakos-$0.26N/AN/AN/AN/AN/A5/5/2025Q1 2025FGENFibroGen$0.03N/AN/AN/A$2.00 millionN/A3/18/2025Q4 2024INKTMiNK Therapeutics-$0.50-$0.62-$0.12-$0.62N/AN/A3/17/2025Q4 2024FGENFibroGen-$0.08-$0.08N/A$0.18$24.91 million$3.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08FGENFibroGenN/A1.281.16INKTMiNK TherapeuticsN/A0.890.89MYNZMainz BiomedN/A0.240.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%FGENFibroGen72.71%INKTMiNK Therapeutics2.87%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipALLKAllakos16.12%FGENFibroGen1.98%INKTMiNK Therapeutics20.60%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableFGENFibroGen570101.04 million98.78 millionOptionableINKTMiNK Therapeutics303.97 million3.15 millionNo DataMYNZMainz Biomed302.32 million1.64 millionNot OptionableMYNZ, FGEN, ALLK, and INKT HeadlinesRecent News About These CompaniesMainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlertApril 27 at 10:08 PM | gurufocus.comMainz Biomed (MYNZ) Advances Colorectal Cancer Test With New StudyApril 27 at 10:08 PM | gurufocus.comMainz Biomed BV: EPS verfehlt Schätzungen um 4,91 $ - Umsatz besser als erwartetApril 23, 2025 | de.investing.comMainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024April 15, 2025 | benzinga.comMainz Biomed-Aktie stürzt auf 52-Wochen-Tief von 2,65 US-DollarApril 5, 2025 | de.investing.comMainz Biomed-Aktie stürzt auf 52-Wochen-Tief von 2,65 US-DollarApril 5, 2025 | de.investing.comEQS-News: Mainz Biomed gibt die Finanzergebnisse für das Jahr 2024 bekannt und informiert über die Unternehmensentwicklung (deutsch)April 2, 2025 | boerse-online.deEQS-News: Mainz Biomed gibt die Finanzergebnisse für das Jahr 2024 bekannt und informiert über die UnternehmensentwicklungApril 2, 2025 | onvista.deMainz Biomed Reports 2024 Financial Results and Provides Corporate UpdateApril 2, 2025 | markets.businessinsider.comMainz Biomed reports FY24 EPS ($22.36) vs ($64.76) last yearApril 1, 2025 | markets.businessinsider.comEQS-News: Mainz Biomed Reports 2024 Financial Results and Provides Corporate UpdateApril 1, 2025 | markets.businessinsider.comMainz Biomed Reports 2024 Financial Success and Strategic AdvancesApril 1, 2025 | tipranks.comMainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer TestMarch 29, 2025 | nasdaq.comMainz Biomed enrolls first patient in its eAArly DETECT 2 studyMarch 28, 2025 | markets.businessinsider.comBuy Rating for Mainz Biomed B.V. Driven by Promising CRC Screening Advancements and Strategic PartnershipsMarch 28, 2025 | tipranks.comEQS-News: Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical StudyMarch 27, 2025 | finanzen.atEQS-News: Mainz Biomed rekrutiert ersten Patienten für seine klinische eAArly DETECT 2-StudieMarch 27, 2025 | boerse.deMainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical StudyMarch 27, 2025 | globenewswire.comStrategic Collaboration and Innovative Biomarkers Drive Buy Rating for Mainz BiomedMarch 21, 2025 | tipranks.comMainz Biomed und Liquid Biosciences machen bahnbrechende Entdeckung von mRNA-Biomarkern für die blutbasierte Erkennung von BauchspeicheldrüsenkrebsMarch 15, 2025 | anlegerplus.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYNZ, FGEN, ALLK, and INKT Company DescriptionsAllakos NASDAQ:ALLK$0.33 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.33 +0.00 (+0.12%) As of 04/25/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.FibroGen NASDAQ:FGEN$0.31 -0.01 (-1.97%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.31 +0.00 (+0.10%) As of 04/25/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.MiNK Therapeutics NASDAQ:INKT$7.70 +0.20 (+2.67%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$7.64 -0.06 (-0.78%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Mainz Biomed NASDAQ:MYNZ$3.53 +0.33 (+10.31%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$3.50 -0.03 (-0.74%) As of 04/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
